Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00108_DB00631_nanopub.RA4hhMcIHKET0Rv4e4r6yIQe0Ivq6OyxSY_2GQ91Ai2tY#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00108_DB00631 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00108_DB00631 label "DDI between Natalizumab and Clofarabine - Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. [drugbank_resource:DB00108_DB00631]" assertion.
- drugbank_resource:DB00108_DB00631 identifier "drugbank_resource:DB00108_DB00631" assertion.
- drugbank_resource:DB00108_DB00631 title "DDI between Natalizumab and Clofarabine - Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab." assertion.
- drugbank:DB00108 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB00631 assertion.
- drugbank:DB00631 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB00631 assertion.